Breaking News Instant updates and real-time market news.

MCRB

Seres Therapeutics

$9.92

0.2 (2.06%)

, NSRGY

Nestle

$83.18

-0.69 (-0.82%)

07:10
06/12/17
06/12
07:10
06/12/17
07:10

Seres Therapeutics initiates SER-109 Phase 3 study

Seres Therapeutics (MCRB) announced the initiation of its Phase 3 SER-109 clinical study, ECOSPOR III, in patients with multiply recurrent C. difficile infection. Based on recent interactions with the U.S. Food and Drug Administration, ECOSPOR III will now be designated a Phase 3 trial and the company expects that this single pivotal study may support SER-109 registration and approval. The initiation of the SER-109 Phase 3 ECOSPOR III study triggers a $20M milestone payment under the company's previously announced development and commercialization collaboration agreement with Nestle Health Science (NSRGY). In partnership with Nestle Health Science, Seres plans to accelerate interactions with European regulatory agencies in the coming months to establish a path toward SER-109 product approval across Europe.

MCRB

Seres Therapeutics

$9.92

0.2 (2.06%)

NSRGY

Nestle

$83.18

-0.69 (-0.82%)

  • 13

    Jun

MCRB Seres Therapeutics
$9.92

0.2 (2.06%)

01/11/17
CANT
01/11/17
NO CHANGE
CANT
Seres still has major opportunities after SER-109 failure, says Cantor
Cantor analyst Bill Tanner says that the failure of the Phase 2 trial of Seres' SER-109 for C. difficile infection, or CDI, "was disappointing." However, the analyst believes that the CDI treatment "mostly represents proof of concept" and that the company has "far greater opportunities" ahead of it. He keeps a $16 price target and an Overweight rating on the shares.
12/16/16
CANT
12/16/16
INITIATION
Target $16
CANT
Overweight
Seres Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started Seres Therapeutics with an Overweight rating and $16 price target.
08/12/16
08/12/16
NO CHANGE
Target $23

Outperform
Seres Therapeutics recent selloff overdone, says FBR Capital
FBR Capital analyst Vernon Bernardino views the selloff in shares of Seres Therapeutics (MCRB) since July 29 as overdone. After the SER-109 Phase II ECOSPOR clinical study in recurrent Clostridium difficile infection did not achieve its endpoint, the analyst cut his price target for the shares to $23 from $43. He points out, however, that development of the company's other clinical-stage assets are partnered with Nestle (NSRGY). Seres' four other collaborations also represent upside potential in the stock, Bernardino tells investors in a research note. He reiterates an Outperform rating on Seres.
08/01/16
LEER
08/01/16
NO CHANGE
Target $12
LEER
Outperform
Seres Therapeutics price target lowered to $12 from $43 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for Seres Therapeutics to $12 from $43 following the company's "surprisingly disappointing" Phase 2 ECOSPOR data, investigating SER-109 in multiply recurrent Clostridium difficile infection, or rCDI, patients. Further, the analyst says that uncertainty for SER-109 raises negative read-through on other follow-on candidates, such as SER-287 for the treatment of mild-to-moderate Ulcerative Colitis and SER-262 in primary CDI. Leerink has an Outperform rating on the shares.
NSRGY Nestle
$83.18

-0.69 (-0.82%)

06/07/17
BREN
06/07/17
DOWNGRADE
BREN
Hold
Nestle downgraded to Hold from Buy at Berenberg
Berenberg analyst James Targett downgraded Nestle to Hold with a price target of 85 francs.
02/02/17
WBLR
02/02/17
NO CHANGE
WBLR
Wyeth Nutrition deal implies $100/share price for Mead, says William Blair
William Blair analyst Jon Andersen says Nestle's (NSRGY) acquisition of Wyeth Nutrition a few years ago, done at 20 times EBITDA, implies a Mead Johnson (MJN) takeover price closer to $100 per share. Reckitt Benckiser (RBGLY) appears to have the financial capacity to get a deal done, Andersen tells investors in a research note after both the company and Mead confirmed the deal talks. The analyst has an Outperform rating on Mead.
02/02/17
SBSH
02/02/17
NO CHANGE
Target $83
SBSH
Buy
Citi calls $90/share price not 'all that great' for Mead Johnson
A deal price for Mead Johnson (MJN) of $90 per share "doesn't seem all that great" given that the shares were at $92 back in July of 2016 and hit $105 in February 2015, Citi analyst David Driscoll tells investors in a research note after Reckitt Benckiser (RBGLY) confirmed overnight that it is in "advanced negotiations" to buy the baby formula maker for $90 per share. The analyst believes Mead shares could be valued at $112 in a takeover. "It is quite easy to wonder if Reckitt isn't coming along at a most opportune time when Mead's EBITDA is depressed, but on a road to recovery," Driscoll writes. The analyst thinks interest from other bidders is likely with press reports as recently as two weeks ago suggesting Nestle (NSRGY) had interest in Mead while other reports suggested interest from Danone (DANOY). Driscoll even ponders if Kraft Heinz (KHC) may "come out of the shadows." In pre-market trading, Mead shares are up 24%, or $16.50, to $86
01/23/17
SBSH
01/23/17
NO CHANGE
Target $88
SBSH
Buy
Citi discusses Mead Johnson momentum, takeout speculation
Citi analyst David Driscoll says his firm's proprietary China surveys continued to suggest on-going positive momentum for Mead Johnson (MJN). Super premium Enfinitas continues to climb the internet bestsellers list while Mead is gaining shelf space, the analyst tells investors in a research note. Driscoll notes that for the third time over the past two and a half years, takeover speculation surfaced in a media report. This time a media report said that Nestle (NSRGY) is interested in Mead. Driscoll's analysis places a $110 takeout value on the company. He keeps a buy rating on Mead with an $88 price target.

TODAY'S FREE FLY STORIES

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Money Supply M2 Weekly Change data reported »

Week of 11/13 Money…

16:37
11/24/17
11/24
16:37
11/24/17
16:37
General news
Fed Balance Sheet Level data reported »

Week of 11/22 Fed Balance…

$NSD

NASDAQ Market Internals

16:17
11/24/17
11/24
16:17
11/24/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
11/24/17
11/24
16:16
11/24/17
16:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/13 Money…

16:15
11/24/17
11/24
16:15
11/24/17
16:15
General news
Breaking General news story  »

Week of 11/22 Fed Balance…

RIC

Richmont Mines

16:01
11/24/17
11/24
16:01
11/24/17
16:01
Hot Stocks
Breaking Hot Stocks news story on Richmont Mines »

Richmont Mines trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGLN

Magellan Health

$83.65

0.35 (0.42%)

15:18
11/24/17
11/24
15:18
11/24/17
15:18
Conference/Events
Magellan Health to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

SGMS

Scientific Games

$52.00

-0.2 (-0.38%)

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Conference/Events
Scientific Games to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
11/24/17
11/24
15:17
11/24/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/24/17
11/24
15:16
11/24/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/24/17
11/24
14:17
11/24/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/24/17
11/24
14:16
11/24/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$21.07

0.44 (2.13%)

, WMT

Wal-Mart

$96.62

0.21 (0.22%)

13:29
11/24/17
11/24
13:29
11/24/17
13:29
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

M

Macy's

$21.07

0.44 (2.13%)

WMT

Wal-Mart

$96.62

0.21 (0.22%)

TGT

Target

$55.88

-1.61 (-2.80%)

BASFY

BASF

$27.39

-0.13 (-0.47%)

TEVA

Teva

$13.70

0.22 (1.63%)

CBS

CBS

$56.54

0.3 (0.53%)

DISH

Dish

$50.43

0.39 (0.78%)

ASX

Advanced Semiconductor

$7.07

0.76 (12.04%)

SPIL

Siliconware Precision

$7.94

-0.05 (-0.63%)

QD

Qudian

$12.22

-3.93 (-24.33%)

BABA

Alibaba

$191.19

1.35 (0.71%)

VIPS

Vipshop

$8.14

-0.3 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Nov

  • 20

    Feb

  • 18

    Mar

AFL

Aflac

$85.00

-0.05 (-0.06%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Conference/Events
Aflac to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

GBL

GAMCO Investors

, WTS

Watts Water

$72.65

0.15 (0.21%)

13:26
11/24/17
11/24
13:26
11/24/17
13:26
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Watts Water »

Gabelli reports 6.69%…

GBL

GAMCO Investors

WTS

Watts Water

$72.65

0.15 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

CC

Chemours

$53.31

0.45 (0.85%)

13:23
11/24/17
11/24
13:23
11/24/17
13:23
Conference/Events
Chemours to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

$NSD

NASDAQ Market Internals

13:17
11/24/17
11/24
13:17
11/24/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/24/17
11/24
13:16
11/24/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$35.74

0.16 (0.45%)

13:09
11/24/17
11/24
13:09
11/24/17
13:09
Conference/Events
Aimmune to hold an investor symposium »

Investor Symposium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PN

Patriot National

12:57
11/24/17
11/24
12:57
11/24/17
12:57
Hot Stocks
Breaking Hot Stocks news story on Patriot National »

Patriot National trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$12.02

-0.4 (-3.22%)

12:55
11/24/17
11/24
12:55
11/24/17
12:55
Options
Cheetah Mobile put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$44.47

0.1828 (0.41%)

12:53
11/24/17
11/24
12:53
11/24/17
12:53
Conference/Events
General Motors holds an investor an analyst webcast »

Management hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Jan

  • 16

    Jan

12:45
11/24/17
11/24
12:45
11/24/17
12:45
General news
Breaking General news story  »

Week of 11/24…

EBAY

eBay

$35.94

-0.02 (-0.06%)

, OSTK

Overstock.com

$61.05

0.6 (0.99%)

12:43
11/24/17
11/24
12:43
11/24/17
12:43
Periodicals
Adobe: Black Friday online sales up 18.4% y/y as of 10:00 am ET, CNBC says »

According to Adobe…

EBAY

eBay

$35.94

-0.02 (-0.06%)

OSTK

Overstock.com

$61.05

0.6 (0.99%)

AMZN

Amazon.com

$1,156.16

16.67 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.